These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 38706781)

  • 1. Connecting impaired fibrinolysis and dyslipidemia.
    Rodriguez M; Zheng Z
    Res Pract Thromb Haemost; 2024 Mar; 8(3):102394. PubMed ID: 38706781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tale of two systems: the intertwining duality of fibrinolysis and lipoprotein metabolism.
    Dai W; Castleberry M; Zheng Z
    J Thromb Haemost; 2023 Oct; 21(10):2679-2696. PubMed ID: 37579878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and biophysical conditions for blood clot lysis.
    Sabovic M; Blinc A
    Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots.
    Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V
    Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis.
    Zheng Z; Mukhametova L; Boffa MB; Moore EE; Wolberg AS; Urano T; Kim PY
    J Thromb Haemost; 2023 Apr; 21(4):1043-1054. PubMed ID: 36759279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. THE FIBRINOLYTIC MECHANISM IN HAEMOSTASIS: A REVIEW.
    STAFFORD JL
    J Clin Pathol; 1964 Sep; 17(5):520-30. PubMed ID: 14207786
    [No Abstract]   [Full Text] [Related]  

  • 7. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.
    Jespersen J
    Dan Med Bull; 1988 Feb; 35(1):1-33. PubMed ID: 3277796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
    Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
    J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood clot contraction: Mechanisms, pathophysiology, and disease.
    Litvinov RI; Weisel JW
    Res Pract Thromb Haemost; 2023 Jan; 7(1):100023. PubMed ID: 36760777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.
    Sakata Y; Aoki N
    J Clin Invest; 1982 Mar; 69(3):536-42. PubMed ID: 7199538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-ordinated spatial propagation of blood plasma clotting and fibrinolytic fronts.
    Zhalyalov AS; Panteleev MA; Gracheva MA; Ataullakhanov FI; Shibeko AM
    PLoS One; 2017; 12(7):e0180668. PubMed ID: 28686711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Internal fibrinolysis of fibrin clots is driven by pore expansion.
    Risman RA; Paynter B; Percoco V; Shroff M; Bannish BE; Tutwiler V
    Sci Rep; 2024 Feb; 14(1):2623. PubMed ID: 38297113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel simultaneous clot-fibrinolysis waveform analysis for assessing fibrin formation and clot lysis in haemorrhagic disorders.
    Nogami K; Matsumoto T; Sasai K; Ogiwara K; Arai N; Shima M
    Br J Haematol; 2019 Nov; 187(4):518-529. PubMed ID: 31335970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of gammaA/gamma' fibrin clots to fibrinolysis.
    Falls LA; Farrell DH
    J Biol Chem; 1997 May; 272(22):14251-6. PubMed ID: 9162058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and biophysical conditions for blood clot lysis.
    Šabovič M; Blinc A
    Pflugers Arch; 2000 Jan; 440(Suppl 1):R134-R136. PubMed ID: 28008511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced plasminogen binding and delayed activation render γ'-fibrin more resistant to lysis than γA-fibrin.
    Kim PY; Vu TT; Leslie BA; Stafford AR; Fredenburgh JC; Weitz JI
    J Biol Chem; 2014 Oct; 289(40):27494-503. PubMed ID: 25128532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.
    Liu JN; Liu JX; Liu Bf BF; Sun Z; Zuo JL; Zhang Px PX; Zhang J; Chen Yh YH; Gurewich V
    Circ Res; 2002 Apr; 90(7):757-63. PubMed ID: 11964367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The myeloperoxidase product, hypochlorous acid, reduces thrombus formation under flow and attenuates clot retraction and fibrinolysis in human blood.
    Misztal T; Golaszewska A; Tomasiak-Lozowska MM; Iwanicka M; Marcinczyk N; Leszczynska A; Chabielska E; Rusak T
    Free Radic Biol Med; 2019 Sep; 141():426-437. PubMed ID: 31279970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemostasis in oral surgery--the possible pathogenetic implications of oral fibrinolysis on bleeding. Experimental and clinical studies of the haemostatic balance in the oral cavity, with particular reference to patients with acquired and congenital defects of the coagulation system.
    Sindet-Pedersen S
    Dan Med Bull; 1991 Dec; 38(6):427-43. PubMed ID: 1802633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
    Konieczynska M; Fil K; Bazanek M; Undas A
    Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.